FORM 8.3 – SPIRE HEALTHCARE GROUP PLC

LONDON, July 01, 2021 – (BUSINESS WIRE) –

FORM 8.3

DISCLOSURE OF THE PUBLIC OPENING POSITION / DISCLOSURE OF TRADING BY

PERSON WITH INTERESTS IN RELEVANT SECURITIES OF 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. IMPORTANT INFORMATION

(a)	Full name of the person required to disclose:	Barclays PLC.
(b)	Owner or person in charge of interest and short
	disclosed positions, if different from 1 (a):
(c)	Name of the provider / recipient of the offer in relation to their	SPIRE HEALTHCARE GROUP PLC
	relevant securities, this form relates to:
(d)	When an exempt fund manager with a
	Provider / offer recipient, indicate this and give the identity of. at
	Provider / recipient of the offer:
(e)	Date position held / transaction carried out:	June 30, 2021
(f)	In addition to the company in 1 (c) above, the discloser makes	NO
	Disclosures Relating to Another Party to the Offer?

2. POSITIONS OF THE DISCLOSURE PERSON

If there are positions or subscription rights for disclosure in more than one class of relevant securities of the provider or target recipient identified in 1 (c), copy Table 2 (a) or (b) (if applicable) for each additional relevant class of collateral.

(a) Holdings and short positions in the relevant securities of the offeror or recipient to which the post-trade disclosure relates (if any)

Class of relevant security:		1p normal
		Interests		Short positions
		number	(%)	number	(%)
(1)	Relevant securities owned
	and / or controlled:	5,606,105	1.40%	97.142	0.02%
(2)	Derivatives with cash settlement:
		21,944	0.01%	5,532,582	1.38%
(3)	Securities derivatives (including options)
	and agreements to buy / sell:	0	0.00%	0	0.00%
	TOTAL:	5,628,049	1.40%	5,629,724	1.40%

All interests and all short positions should be disclosed.

Details of any open equity settled derivative positions (including traded options) or agreements to buy or sell relevant securities should be disclosed on Supplementary Form 8 (Open Positions).

(b) Subscription rights for new securities (including options for directors and other employees)

Class of relevant securities for which subscription rights exist:
Details, including the nature of the rights involved and the relevant percentages:

3. ACTION (IF NECESSARY) BY THE PERSON MAKING THE DISCLOSURE

The story goes on

If trades have taken place in more than one class of relevant securities of the offeror or recipient named in 1 (c), copy Table 3 (a), (b), (c) or (d) (as required) for each additional class of the relevant security traded.

The currency must be specified for all prizes and other amounts of money.

(a) Purchases and Sales

Class of relevant	Buy / sell	number of	price per unit
security		Securities
1p normal	purchase	386	2.4650 GBP
1p normal	purchase	387	2.4700 GBP
1p normal	purchase	4,400	£ 2,4666
1p normal	purchase	106,473	2.4600 GBP
1p normal	sale	1,755	£ 2.4678
1p normal	sale	5,227	2.4669 GBP
1p normal	sale	71,059	2.4600 GBP

(b) Derivatives transactions with cash settlement

Class of	product	Type of trade	number of	price per
relevant	description		reference	unit
security			Securities
1p normal	TO DECEIVE	Long	500	2.4648 GBP
1p normal	TO DECEIVE	Long	2,082	2.4686 GBP
1p normal	CFD	Long	67,774	2.4600 GBP
1p normal	TO DECEIVE	Short	1,249	£ 2.4651
1p normal	CFD	Short	32,318	2.4601 GBP
1p normal	CFD	Short	73,679	2.4600 GBP

(c) Securities settlement derivatives transactions (including options)

(i) Write, Sell, Buy, or Vary

Class of the relevant security	Product description eg call option	Write, buy, sell, vary etc.	Number of securities to which the option relates	Exercise price per share	Art e.g. American, European etc.	Expiration date	Option money paid / received per unit

(ii) exercise

Class of the relevant security	Product description e.g. call option	Exercise / exercise against	Number of securities	Exercise price per share

(d) Other transactions (including subscription of new securities)

Class of the relevant security	Type of trade e.g. subscription, exchange	details	Price per unit (if applicable)

4. FURTHER INFORMATION

(a) Compensation and Other Trade Agreements

Details of any indemnification or option agreements, or agreements or arrangements, formal or informal, in relation to relevant securities that may constitute an incentive to trade or to refrain from doing business by the disclosing person and any party to the offer or any other person Joint action with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements, or understandings, state “none”.

None

(b) agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement, or arrangement, whether formal or informal, between the person making the disclosure and another person relating to: (i) the voting rights of all relevant securities under an option; or (ii) the voting rights or the future acquisition or disposal of relevant securities to which a derivative relates: If there are no such agreements, arrangements, or understandings, state “none”.

None

(c) Appendices

Has a supplementary form 8 (vacancies) been attached?	NO
Disclosure date:	July 1, 2021
Contact name:	Regulatory operations for large holdings
Phone number:	020 3134 7213

Disclosures under Rule 8 of the Code must be made to a regulatory information service.

The panel’s Market Surveillance Unit is available for consultations regarding the disclosure requirements of the Code on +44 (0) 20 7638 0129.

* If the person required to disclose is a natural person, there is no need to provide a telephone number if contact information has been provided to the market surveillance unit of the panel.

The Code can be viewed on the panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005455/de/

contacts

BARCLAYS PLC

source https://dailyhealthynews.ca/form-8-3-spire-healthcare-group-plc/